Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis

He,Yi‑Fu; Luo,Hui‑Qin; Wang,Wei; Chen,Jian; Yao,Yi‑Wei; Cai,Shan‑Bao; He,Jie; Yan,Ying; Wu,Shu‑Sheng; Hu,Xiao‑Xiu; Ke,Li‑Hong; Niu,Jia‑Yu; Li,Hui‑Min; Ji,Chu‑Shu; Hu,Bing

doi:10.3892/ol.2015.3081

Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis

Authors:
- Yi‑Fu He
- Hui‑Qin Luo
- Wei Wang
- Jian Chen
- Yi‑Wei Yao
- Shan‑Bao Cai
- Jie He
- Ying Yan
- Shu‑Sheng Wu
- Xiao‑Xiu Hu
- Li‑Hong Ke
- Jia‑Yu Niu
- Hui‑Min Li
- Chu‑Shu Ji
- Bing Hu
View Affiliations

Affiliations: Department of Medical Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical Univeristy, Hefei, Anhui 230001, P.R. China, Department of Orthopedics, Anhui Provincial Cancer Hospital, Hefei, Anhui 230001, P.R. China, Department of Pathology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230001, P.R. China, Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230001, P.R. China
Published online on: March 27, 2015 https://doi.org/10.3892/ol.2015.3081
Pages: 2706-2712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to analyze the clinical characteristics and prognosis-related factors of non-small cell lung cancer (NSCLC) patients with bone metastases at the time of diagnosis. A total of 46 NSCLC patients with skeletal metastases at the time of diagnosis from Anhui Provincial Hospital and Anhui Provincial Cancer Hospital Affiliated to Anhui Medical University (Hefei, China) between February 2010 and February 2012 were investigated retrospectively. The median age was 58 years, with a range of 40‑80 years, the ratio of males and females was 2:1, and adenocarcinoma and squamous cell carcinoma accounted for 71.7 and 28.3% of cases, respectively. Furthermore, 84.8% of patients exhibited multiple skeletal metastases at more than two sites and 54.3% of patients experienced skeletal‑related events at the time of diagnosis. The median overall survival (OS) time of the patients was 237 days, and Kaplan‑Meier analysis demonstrated that patients with adenocarcinoma (P=0.002), single bone metastases (P=0.023), an Eastern Cooperative Oncology Group performance status of 0‑1 (P<0.001) or positive expression of estrogen receptor (ER)‑β (P=0.039) exhibited significantly longer survival times. Furthermore, multivariate analysis identified the following independent predictors of OS: Tumor subtype (P=0.022), the number of bone metastases (P=0.016) and an ER‑β‑positive tumor (P=0.035). In the cohort of NSCLC patients with bone metastases at the time of diagnosis, adenocarcinoma and multiple skeletal metastases were most common.

View Figures

View References

1	Chen W, Zheng R, Zhang S, et al: Annual report on status of cancer in China, 2010. Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
2	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243–6249. 2006. View Article : Google Scholar
3	Tsuya A, Kurata T, Tamura K, et al: Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 57:229S–232S. 2007. View Article : Google Scholar
4	Beattie CW, Hansen NW and Thomas PA: Steroid receptors in human lung cancer. Cancer Res. 45:4206–4214. 1985.PubMed/NCBI
5	Santarpia L, Koch CA and Sarlis NJ: Hypercalcemia in cancer patients: pathobiology and management. Horm Metab Res. 42:153–164. 2010. View Article : Google Scholar : PubMed/NCBI
6	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–55. 1982. View Article : Google Scholar : PubMed/NCBI
7	Krawczyk P, Nicoś M, Ramlau R, et al: The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma. Pathol Oncol Res. 20:107–112. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lee Y, Chung JH, Kim SE, et al: Adenosquamous carcinoma of the lung: CT, FDG PET, and clinicopathologic findings. Clin Nucl Med. 39:107–112. 2014.PubMed/NCBI
9	Yuan L, Zhang J, Tan H, et al: An analysis of 1657 inpatients with lung cancer from 2001 to 2008. Ning xia yi ke da xue xue bao. 32:374–377. 2010.
10	Bae HM, Lee SH, Kim TM, et al: Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer. 77:572–577. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Jin B, Shao M, et al: Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumour Biol. 35:4921–8. 2014. View Article : Google Scholar : PubMed/NCBI
12	Shi Y, Au JS, Thongprasert S, et al: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162. 2014. View Article : Google Scholar : PubMed/NCBI
13	Duan JC, An TT, Wu MN, et al: Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi. 35:323–328. 2012.[(In Chinese)]. PubMed/NCBI
14	Ohashi R, Takahashi K, Miura K, et al: Prognostic factors in patients with inoperable non-small cell lung caner - an analysis of long-term survival patients. Gan To Kagaku Ryoho. 33:1595–1602. 2006.PubMed/NCBI
15	Ivanova M, Abner S, Pierce W Jr and Klinge C: Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses. Proteome Sci. 9:602011. View Article : Google Scholar : PubMed/NCBI
16	Monica V, Longo M, Felice B, et al: Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy. Clin Lung Cancer. 13:416–423. 2012. View Article : Google Scholar : PubMed/NCBI
17	Pietras RJ, Márquez DC, Chen HW, et al: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 70:372–381. 2005. View Article : Google Scholar : PubMed/NCBI
18	Stabile LP, Lyker JS, Gubish CT, et al: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 65:1459–1470. 2005. View Article : Google Scholar : PubMed/NCBI
19	Tang H, Liao Y, Chen G, et al: Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β. Med Oncol. 29:2640–2648. 2012. View Article : Google Scholar : PubMed/NCBI
20	Siegfried JM, Hershberger PA and Stabile LP: Estrogen receptor signaling in lung cancer. Semin Oncol. 36:524–531. 2009. View Article : Google Scholar : PubMed/NCBI
21	Rodriguez-Lara V, Peña-Mirabal E, Baez-Saldaña R, et al: Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res. 45:158–169. 2014. View Article : Google Scholar : PubMed/NCBI
22	Siegfried JM: Smoking out reproductive hormone actions in lung cancer. Mol Cancer Res. 12:24–31. 2014. View Article : Google Scholar : PubMed/NCBI
23	Schwartz AG, Prysak GM, Murphy V, et al: Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
24	Navaratnam S, Skliris G, Qing G, et al: Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. Horm Cancer. 3:93–100. 2012. View Article : Google Scholar : PubMed/NCBI
25	Lixian Z: Serum estrogen levels of lung cancer patients and estrogen receptor expression in lung cancer tissue and its clinical pathological significance. (unpublished PhD thesis). Fujian Medical University 2013
26	Kawai H, Ishii A, Washiya K, et al: Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 11:5084–5089. 2005. View Article : Google Scholar : PubMed/NCBI
27	Mauro LV, Dalurzo M, Carlini MJ, et al: Estrogen receptor β and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer. Oncol Rep. 24:1331–1338. 2010.PubMed/NCBI
28	Rossi A, Chiodini P, Sun JM, et al: Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 15:1254–1262. 2014. View Article : Google Scholar : PubMed/NCBI
29	Gallo D, De Stefano I, Grazia Prisco M, et al: Estrogen receptor beta in cancer: an attractive target for therapy. Curr Pharm Des. 18:2734–2757. 2012. View Article : Google Scholar : PubMed/NCBI
30	Du KQ and Jia CX: The expression of estrogen receptor and endocrine therapy of non-small cell lung cancer with the expression of estrogen receptor and endocrine therapy. Acta Acad Med Xuzhou. 30:278–280. 2010.
31	Wang XY, Wang Y and Liu HC: Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells. Biomed Pharmacother. 65:525–528. 2011. View Article : Google Scholar : PubMed/NCBI
32	Pesatori AC, Carugno M, Consonni D, et al: Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO). Br J Cancer. 109:1954–1964. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ko JC, Chiu HC, Syu JJ, et al: Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells. Biochem Pharmacol. 88:119–127. 2014. View Article : Google Scholar : PubMed/NCBI